Dr Ranjit Manchanda

Dr Ranjit Manchanda

MD, MRCOG, PhD
Centre: Centre for Experimental Cancer Medicine
Clinical Senior Lecturer, Consultant Gynaecological Oncologist
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory

My main research areas are:

  • Risk prediction, screening and prevention of ovarian and endometrial cancer
  • Population based approach(es) to genetic testing for risk stratification and cancer prevention
  • Targeted surgical approaches for prevention of gynaecological cancer
  • Familial gynaecological cancer

Research Details

Research interests

Population based genetic testing for cancer prevention

Development and implementation of a population based risk stratification approach for prediction and prevention of gynaecological cancers

Familial ovarian and endometrial cancer screening

Management of familial gynaecological cancer such as: breast and/or ovarian cancer families, Lynch Syndrome; Cowden’s Syndrome

Targeted surgical strategies for prevention of tubal/ovarian cancer: risk reducing salpingo-oophorectomy, opportunistic salpingectomy, salpingectomy and delayed oophorectomy

Genetic testing of population based case series for ascertainment of high penetrance genes

Gynaecological Oncology Training; Role and importance of accredited training 

GCaPPS (Genetic Cancer Prediction through Population Screening) Study

We use the Ashkenazi Jewish population as a population model and BRCA1/2 gene mutations as a disease model for research into a population based approach to testing for high penetrance cancer genes. GCaPPS is a randomised trial (ISRCTN73338115) comparing the family history and population based approaches to genetic testing for BRCA mutations in the North London Jewish population.

PROMISE (Predicting Risk of Ovarian Malignancy Improved Screening and Early Detection) research programme

PROMISE is a multicentre, international programme bringing together 36 researchers from a number of leading centres to address the challenge of effectively translating advances in risk stratification, screening and early detection for ovarian cancer into population-based interventions by developing and validating models for risk stratification, early detection and diagnosis of ovarian cancer which incorporate clinical, epidemiological, genetic, proteomic and imaging data and evaluating health behavioural aspects of their application to large populations. A feasibility study for population testing using outputs from the programme is planned for 2016.

Ovarian & Endometrial Cancer Screening

We collaborate with the team at Dept of Women’s Cancers, University College London on ovarian and endometrial cancer screening research projects.

UKFOCSS (United Kingdom Familial Ovarian Cancer Screening Study): National trial for screening for Ovarian cancer in high risk women.

Targeted surgical approaches for ovarian cancer prevention

We are interested in developing and evaluating targeted, personalised strategies for prevention of ovarian and tubal cancer.

Clinical interests

Advanced complex laparoscopic surgery in gynaecological oncology

Ultraradical debulking surgery for ovarian cancer

Familial gynaecological cancer

My clinical practice is at the Royal London Hospital, Barts Health NHS Trust.

Profile

I joined Barts Cancer Institute as a Clinical Senior Lecturer and Consultant Gynaecological Oncologist in June 2015. I previously worked as a Consultant Gynaecological Oncologist at St Bartholomew’s Hospital & was an Honorary Senior Lecturer at University College London, UK.

Following general training in obstetrics and gynaecology, I completed a PhD in gynaecological oncology at UCL, plus subspecialty training in gynaecological oncology from UCLH and St Bart's. I have served as the president of the European Network of young Gynaecological Oncologists (ENYGO) and a member of the European Society of Gynaecological Oncology (ESGO) council (2011-2013).

I am Acting-PI, research lead and co-ordinator of the ‘Genetic Cancer Prediction through Population Screening’ (GCaPPS) study; a co-investigator of the ‘Predicting Risk of Ovarian Malignancy, Improving Screening and Early detection’ (PROMISE) 2016 programme and member of the ‘UK Familial Ovarian Cancer Screening Study’ (UKFOCSS) team. I lead the St Bart's Hospital familial gynaecological cancer clinic team.

I am also actively involved in gynaecological oncology training issues, have helped develop and establish ENYGO (European Network of Young Gynaecological Oncologists) from its inception and both led and undertaken a number of initiatives for European and international trainees in gynaecological oncology.

Previous posts

Mar-2014 – May 2015 - Locum Consultant Gynaecological Oncologist (St Bartholomew's Hospital) & Honorary Sr. Lecturer, Women’s Cancer (University College London)

Feb 2010 – Feb 2014 - NIHR Walport Clinical Lecturer & Sub-Specialty trainee Gynaecological Oncology (University College London Hospital, Bart’s Hospital, University College London)

Oct 2013 – Nov 2013 - Visiting Fellow (Bydgoszcz Cancer Centre, Poland)

Feb2007 – Jan 2010 - Clinical Research Fellow, Gynaecological Oncology (University College London)

Sep 2002 –  Jan 2007 - Specialist Registrar Obstetrics & Gynaecology East of England Training Programme (Cambridge rotation)

Aug 2001 – Aug 2002 - Acting Registrar Obstetrics & Gynaecology Southend Hospital

July 2000 – July 2001 - Indian Council Medical Research Fellowship, Obstetrics & Gynaecology, All India Institute of Medical Sciences, India

July 1993 – Oct 1999 - Junior and Senior Resident Obstetrics & Gynaecology (6 year training programme), All India Institute of Medical Sciences (AIIMS), India

Qualifications

2014 CCT Obstetrics & Gynaecology and Gynaecological Oncology
2014 Subspecialist Training in Gynaecological Oncology
2014 BSCCP accreditation in Colposcopy
2013 PhD (Gynaecological Oncology, University College London)
2005 MRCOG (Royal College of Obstetricians & Gynaecologists, London)
1996 MD (Thesis & Post Graduate Degree, Obstetrics & Gynaecology, AIIMS, Delhi)
1993 MBBS (All India Institute of Medical Sciences (AIIMS), Delhi)

Other

NIHR Leadership Programme for Trainees Nov 2009 – Jan 2011, Ashridge Business School

Funding

2015-2017 Barts Charity Use of Plasmajet in ultra-radical surgery for advanced Ovarian Cancer
2011-2016 Cancer Research UK & The Eve Appeal PROMISE 2016: Predicting Risk of Ovarian Malignancy Improved Screening and Early Detection Programme
2011-2013 European Society of Gynaecological Oncology (ESGO) European Network of Young Gynaecological Oncologists (ENYGO) budget grants
2008-2016 The Eve Appeal Genetic Cancer Prediction through population Screening (GCaPPS)

Key Publications

Cost effectiveness of population screening for BRCA mutations in Ashkenazi-Jewish women compared to family-history based testing.
Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, and Jacobs I. J Natl Cancer Inst. (2015); 107(1) PMID: 25435542

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomised controlled trial.
Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, R, Jacobs C, Tomlinson I, McGuire A, Beller U, Menon U, and Jacobs I. J Natl Cancer Inst. (2015); 107(1) PMCID: PMC4301703

A Risk Prediction Algorithm for Ovarian Cancer Incorporating BRCA1, BRCA2, Common Alleles and Other Familial Effects.
Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, Manchanda R, Easton D, Jacobs I, Pharoah P, Antoniou A. J Med Genet. (2015); 0:1–11. PMID: 26025000

The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO).
Manchanda R, Godfrey M, Wong-Taylor LA, Halaska MJ, Burnell M, Grabowski JP, Gultekin M, Haidopoulos D, Zapardiel I, Vranes B, Kesic V, Zola P, Colombo N, Verheijen R, Bossart M, Piek. J. Ann Oncol. (2013); 24(4), 944-52 PMID: 23172637


Further Publications

For additional publications, please click here

My main research areas are:

  • Risk prediction, screening and prevention of ovarian and endometrial cancer
  • Population based approach(es) to genetic testing for risk stratification and cancer prevention
  • Targeted surgical approaches for prevention of gynaecological cancer
  • Familial gynaecological cancer

External Activities

  • Scientific Adviso r- BRCA Umbrella
  • Barts Gynae Clinical Trials Group
  • Spokesperson for The Eve Appeal
  • Member Trial Steering Committee, UKFOCSS trial
  • Member Trial management and Trial Steering Committees GCaPPS trial
  • Member ESGO Task Force for Prevention and Early diagnosis of Women Cancers (ENPIGO), 2014-
  • Accreditation of ESGO Gynae-oncology training centres
  • NCRI Ovarian Cancer Subgroup
  • President ENYGO (European Network of Young Gynaecological Oncologists) Sep 2011 – Oct 2013
  • ESGO (European Society Gynaecological Oncology) Council member Sep 2011- Oct 2013
  • Member Meeting committee, Member Fellowships committee, Member Training & Accreditation committee of ESGO Council, Sep 2011 – Oct 2013
  • Organised/ directed Cadaveric workshops on advanced laparoscopic surgery in gynaecological oncology: Bangalore, India 2015 (AGOI); London, UCLH (ESGO) 2012
  • Organisation of numerous national and international workshops, meetings and initiatives related to training in gynaecological oncology
  • Organisation & Programme Chair of Young Doctors Session (YDS): First worldwide international conference for gynaecological oncology trainees/fellows, IGCS, Vancouver 2012
  • Organisation of number of national and international conferences in gynaecological oncology
  • Member Clinical Trials Forum, UCLH (2010-2014)
  • Member and then Chair, Executive committee ENYGO (European Network of Young Gynaecological Oncologists), the trainee arm of ESGO. Sep 2009- Oct 2013
  • UK representative of ENYGO (European Network of Young Gynaecological Oncologists). 2009- Mar 2013
  • Member academic trainees committee, EGA Institute for Women’s Health (UCL) 2007-2009

News

  • Jul 2015: Invited Speaker, Opportunistic Bilateral Salpingectomy at benign gynaecological surgery. BGCS meeting, Newcastle.
  • Jun 2015: Invited Speaker, Opportunistic Bilateral Salpingectomy at benign gynaecological surgery should be undertaken in a clinical trial. BSGE Silver Jubilee Scientific Meeting, London
  • Apr 2015: Invited Speaker, Management of gynaecological cancers in Lynch Syndrome. Lynch Syndrome UK meeting Birmingham.
  • Mar 2015: Invited Speaker, Testing in the Jewish population for the BRCA cancer predisposing genes. All Party Parliamentary Group Presentation, West Minister, London.
  • Mar 2015: Invited Speaker & Course Director, First Indian Cadaveric Laparoscopic Workshop in Gynaecological Oncology, Bangalore, India 
  • Feb 2015: Speake r- UK trial proposal on Risk Reducing Salpingectomy & Delayed Oophorectomy (RRSDO) in BRCA1/2 carriers, NCRI Ovarian Cancer subgroup meeting, Glasgow
  • Feb 2015: Invited Speaker - London Cancer Gynaecology & Breast Combined Research Day. Risk Reducing Salpingectomy and Delayed Oophorectomy- Proposal for a UK cohort Study.
  • Oct 2014: Invited Speaker - ESGO Masterclass in Gynaecological Oncology, Madrid, 3-4 Oct 2014
  • Sep 2014: Invited Speaker - BRCA testing in high risk populations. 10th Biennial Ovarian Cancer Research Symposium, Marsha Rivkin Centre for Ovarian Cancer research and American Association of Cancer Research, Seattle, Washington. CRUK report

GCaPPS News Coverage

  • Medical News Today: New research shows current approach for detecting BRCA gene mutations misses people at high risk of cancer
  • Jewish News: Ashkenazi cancer study leads to calls for overhaul of screening process
  • Health News: Family history screening misses people at high risk of cancer
  • Bioscience Technology: Current Mutation Detection Process Misses People at High Risk of Cancer
  • UCL: Family history screening misses people at high risk of cancer
  • Press Release Point: Family history screening misses people at high risk of cancer
  • Newry Times: ‘Genetic Testing must be broadened to help cancer sufferers’ – Ritchie
  • Medical XpressManchester University: Current way of detecting gene mutations misses people at high risk of cancer
  • The Independent: Blood tests for cancer gene mutations ‘more effective’ than just taking family history

Others

BBC News, WebMD, Pan-European Networks

See other researchers working on:

Clinical Trials Genetics Ovarian Cancer
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.